tetano
Editor, Senior Moderator
Rev Med Virol
. 2026 May;36(3):e70158.
doi: 10.1002/rmv.70158.
Comparative Effectiveness of High-Dose and Standard-Dose Influenza Vaccines for Hospitalisation and Mortality in Adults Aged 65 and Older: An Updated Systematic Review and Meta-Analysis
Bilal Wazir Khan[SUP] 1 [/SUP], Muhammad Huzaifa Khattak[SUP] 1 [/SUP], Muhammad Maaz Amjad[SUP] 1 [/SUP], Shahreena Athar Siddiqui[SUP] 2 [/SUP], Tayyaba Ikram Qazi[SUP] 1 [/SUP], Hamdullah Rehmat[SUP] 1 [/SUP], Muhammad Faaz Khan[SUP] 1 [/SUP], Haris Wazir Khan[SUP] 3 [/SUP], Affan Masaud Mian[SUP] 1 [/SUP], Mohsin Ullah[SUP] 1 [/SUP], Umer Zaryab Khan[SUP] 1 [/SUP], Muhammad Abdur Rafay[SUP] 4 [/SUP], Sajjad Ghanim Al-Badri[SUP] 5 6 [/SUP], Zaryab Bacha[SUP] 1 [/SUP]
Affiliations
This updated systematic review and meta-analysis evaluated the relative vaccine effectiveness (rVE) of high-dose inactivated influenza vaccine (HD-IV) versus standard-dose (SD-IV) in adults ≥ 65 years for key clinical outcomes, including hospitalisations and mortality. Conducted in accordance with PRISMA guidelines, PubMed, Embase, and the Cochrane Library were searched for randomised controlled trials. Primary outcomes were pneumonia and influenza (P&I) hospitalisation, all-cause hospitalisation, and all-cause mortality, while secondary outcomes included hospitalisation for cardiorespiratory disease, influenza-related hospitalisation, laboratory-confirmed influenza hospitalisation, and serious adverse events (SAEs). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using fixed-effect models. Across 586,188 participants, HD-IV reduced P&I hospitalisation (rVE 12.0%), increasing to 22.0% in sensitivity analysis. For all-cause hospitalisation (∼600,000 participants), rVE was 4.0%, while no significant reduction was observed for all-cause mortality (rVE = 2.0%). Subgroup analyses suggested greater benefits in individuals without cardiovascular disease and those aged 65-79 years. HD-IV also showed strong protection against influenza-specific outcomes (rVE 39% for influenza hospitalisation; 32% for laboratory-confirmed influenza hospitalisation), with no significant difference in SAEs between groups. Overall, HD-IV provides superior protection compared with SD-IV against P&I and all-cause hospitalisation in older adults, with the greatest benefits among younger seniors and those without cardiovascular disease. These findings support prioritising HD-IV to reduce influenza burden in the elderly, although benefits appear limited in adults aged > 80 years.
Keywords: high‐dose inactivated influenza vaccine; hospitalisation; influenza vaccine; meta‐analysis; older adults.
. 2026 May;36(3):e70158.
doi: 10.1002/rmv.70158.
Comparative Effectiveness of High-Dose and Standard-Dose Influenza Vaccines for Hospitalisation and Mortality in Adults Aged 65 and Older: An Updated Systematic Review and Meta-Analysis
Bilal Wazir Khan[SUP] 1 [/SUP], Muhammad Huzaifa Khattak[SUP] 1 [/SUP], Muhammad Maaz Amjad[SUP] 1 [/SUP], Shahreena Athar Siddiqui[SUP] 2 [/SUP], Tayyaba Ikram Qazi[SUP] 1 [/SUP], Hamdullah Rehmat[SUP] 1 [/SUP], Muhammad Faaz Khan[SUP] 1 [/SUP], Haris Wazir Khan[SUP] 3 [/SUP], Affan Masaud Mian[SUP] 1 [/SUP], Mohsin Ullah[SUP] 1 [/SUP], Umer Zaryab Khan[SUP] 1 [/SUP], Muhammad Abdur Rafay[SUP] 4 [/SUP], Sajjad Ghanim Al-Badri[SUP] 5 6 [/SUP], Zaryab Bacha[SUP] 1 [/SUP]
Affiliations
- PMID: 42052799
- DOI: 10.1002/rmv.70158
This updated systematic review and meta-analysis evaluated the relative vaccine effectiveness (rVE) of high-dose inactivated influenza vaccine (HD-IV) versus standard-dose (SD-IV) in adults ≥ 65 years for key clinical outcomes, including hospitalisations and mortality. Conducted in accordance with PRISMA guidelines, PubMed, Embase, and the Cochrane Library were searched for randomised controlled trials. Primary outcomes were pneumonia and influenza (P&I) hospitalisation, all-cause hospitalisation, and all-cause mortality, while secondary outcomes included hospitalisation for cardiorespiratory disease, influenza-related hospitalisation, laboratory-confirmed influenza hospitalisation, and serious adverse events (SAEs). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using fixed-effect models. Across 586,188 participants, HD-IV reduced P&I hospitalisation (rVE 12.0%), increasing to 22.0% in sensitivity analysis. For all-cause hospitalisation (∼600,000 participants), rVE was 4.0%, while no significant reduction was observed for all-cause mortality (rVE = 2.0%). Subgroup analyses suggested greater benefits in individuals without cardiovascular disease and those aged 65-79 years. HD-IV also showed strong protection against influenza-specific outcomes (rVE 39% for influenza hospitalisation; 32% for laboratory-confirmed influenza hospitalisation), with no significant difference in SAEs between groups. Overall, HD-IV provides superior protection compared with SD-IV against P&I and all-cause hospitalisation in older adults, with the greatest benefits among younger seniors and those without cardiovascular disease. These findings support prioritising HD-IV to reduce influenza burden in the elderly, although benefits appear limited in adults aged > 80 years.
Keywords: high‐dose inactivated influenza vaccine; hospitalisation; influenza vaccine; meta‐analysis; older adults.